Teva launches generic high blood pressure treatment


As first to file, Teva has 180 days generic marketing exclusivity for Novartis's Exforge.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has launched the generic equivalent of Exforge HCT (Amlodipine, Valsartan, Hydrochlorothiazide) tablets in the United States.

Teva was first to file, opening the generic market for the product, as well as making the product eligible for 180 days of marketing exclusivity.

Exforge HCT (Amlodipine, Valsartan, Hydrochlorothiazide) tablets for the treatment of high blood pressure, is marketed by Novartis Pharmaceuticals, and had annual sales of $158 million in the US, according to IMS data as of September 2014.

Published by Globes [online], Israel business news - - on December 2, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018